Blockchain Registration Transaction Record

Bio-Path Holdings Advances RNAi Therapeutics with DNAbilize® Platform

Bio-Path Holdings innovates with DNAbilize® platform, advancing RNAi therapeutics for cancer and metabolic diseases, offering new hope for patients.

The advancements by Bio-Path Holdings in RNAi therapeutics could revolutionize the treatment of cancer and metabolic diseases, offering hope to patients with limited options. The company's innovative DNAbilize® platform addresses key challenges in drug delivery, potentially leading to more effective and safer treatments. This news is crucial for investors, healthcare professionals, and patients alike, as it highlights the potential for groundbreaking therapies in the near future.